Latest News

Avadel’s stock falls 21% after disclosing new FDA request for experimental narcolepsy drug


Shares of Avadel Pharmaceuticals PLC

tumbled 21.6% in premarket trading on Thursday after the company said in a securities filing that the Food and Drug Administration requested additional information for its experimental narcolepsy drug. Avadel said it now expects to get a FDA decision on the drug, FT218, by June of next year. The company’s stock is down 58.1% this year, while the S&P 500

has declined 16.5%.

Morgan Stanley downgrades Gap after weak first-quarter report, says stock has further downside

Previous article

Stocks making the biggest moves premarket: Big Lots, Hibbett, Pinduoduo and others

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News